Chinese clinical-stage, oncology-focused biotech player IASO Biotherapeutics on Monday announced the completion of its $60-million Series B round of financing led by Hillhouse’s early-stage venture capital fund GL Ventures.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com